COVID-19 Information for Researchers at BRI
Resource for researchers at BRI in light of the recent COVID-19 situation:
- COVID-19 CRP/IRB Memo & FAQ for Researchers
- SOP - Clinical Research During a Pandemic
- Guide to Risk/Benefit Analysis
- Risk/Benefit Tool
FDA and NIH detailed guidelines:
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
- CDC Coronavirus (COVID-19) Page
- Guidance for NIH-funded Clinical Trials & Human Subjects Studies Affected by COVID-19
Research involving COVID-19 samples at BRI must consider the following best practices and guidelines:
Please contact one of the RPD members below or the Clinical Research Program if you need assistance or have questions.
- Sarah Valenti, JD, CIP, Research Protections Manager
- Annthea Vining, Regulatory Specialist
- Rainier Reyes, Regulatory Specialist
- Jason Tharpe, Regulatory Specialist
- Tessa Woods, Regulatory Specialist